atients with primary progressive multiple sclerosis (PPMS) tend to experience more cognitive impairment than patients with relapsing-remitting MS (RRMS), according to a study that involved extensive neuropsychological testing of participants.
The study sheds new light in particular on the cognitive profi le of PPMS, a disease that MS experts say has been hard to characterize.
"Although PPMS is mainly characterized clinically by spinal cord involvement, we observed that cognitive functions are frequently impaired," Bruno Brochet, MD, a study coauthor told Neurology Today. "Cognitive impairment appears to be more frequent and severe and concerns a wider range of cognitive functions than in relapsing-remitting MS."
The study, published online Mar. 20 ahead of the print edition of Neurology, was conducted at the University of Bordeaux in France, where Dr. Brochet is a professor of neurology.
BY S U S A N K R E I M E R
E ach year in her solo neurology practice, Elaine C. Jones, MD, experiences a surge in overhead costs amid a decline in Medicare reimbursement rates. She expects to feel the pinch even more in 2013.
"It is going to be a big hit," said Dr. 
BY M A RY B E T H N I E R E N G A RT E N
I n a move that several leading Alzheimer' s disease (AD) experts welcomed, the Food and Drug Administration (FDA) issued a new guidance document in February refocusing drug development and treatment for Alzheimer' s disease to earlier stages of disease. Among its policy changes, the FDA proposed loosening regulations requiring patients to have both cognitive and functional impairment to be eligible for clinical trials.
The proposed changes, which were explained further in a Mar. 13 paper in the New England Journal of Medicine, refl ect an emerging consensus among AD clinicians and investigators that treating APRIL 18, 2013 | VOLUME 13 | ISSUE 8
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Continued on page 22 "In all likelihood, there are many other factors that come into play to produce the same clinical picture in a sporadic, nongenetic 85-year-old man with the disease than you see with a 45-year-old man with a genetic mutation with the disease," he said.
Dr. Petersen is less convinced, therefore, that data concerning markers in the early onset cases will translate directly to the late onset non-genetic cases. "I think it is a great idea, but treatments that may be effective in early-onset cases may be less effective in late-onset cases, but the strategy is worth pursuing." Dr. Petersen also questioned the validity of using a composite scale such as the CDR-SB suggested by the FDA, particularly for patients with mild cognitive impairment in whom, in his opinion, the test may be insensitive in picking up subtle changes of the disease. "It may not be the best clinical marker in that stage of the disease," he said.
WHAT ABOUT PATIENT SAFETY?
Just as the FDA is often criticized for moving slowly in approving drugs, an equally strong pressure comes from those who warn about the risks of approving drugs too fast to ensure their safety. Days after publication of the FDA statement, the editorial board of The New York Times on Mar. 17 questioned whether patient safety could be compromised by giving patients with no evidence of disease drugs that may be effective, but have side effects.
Saying he thought the editorial was somewhat shortsighted and inappropriately conservative given the challenges of fi nding effective treatments for AD, Dr. Knopman emphasized that safety and risk-benefi t ratios are always an important issue. "Nobody is going to approve a drug for use in cognitively normal people unless it is safe and unless there is strong evidence that it can delay the biological progression of Alzheimer' s disease," he said. "I don't think the FDA criteria pose a risk." Dr. Morris also emphasized the need for safety, but noted that by study design, the current prevention trials will only give anti-Abeta therapy to people who are at high risk of developing AD and already have Abeta abnormalities.
Dr. Petersen acknowledged the risk of giving a drug with potential infl ammatory side effects to people without symptoms of the disease, but said some bold and perhaps risky steps are needed.
Despite some reservations about the details of the FDA proposal, he emphasized that he agrees with its essence. "I support this approach because there has not been a new drug approved for AD by the FDA in 10 years," he said, adding that perhaps one reason for this could be a fl aw in the design of clinical trials that have not permitted intervening earlier in the course of disease.
•
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emphasized the need for safety, but noted that by study design, the current prevention trials will only give anti-Abeta therapy to people who are at high risk of developing AD and already have Abeta abnormalities. "The PPMS patients presented with a wide range of cognitive defi cits in information processing speed (IPS), attention, working memory, executive function, and verbal episodic memory, whereas the impairments in RRMS were limited to IPS and working memory," when compared with healthy controls in the study, the researchers reported.
LINK UP FOR MORE
The study authors noted that there is little published research on the cognitive dysfunction that occurs with PPMS as compared with RRMS, and the fi ndings have not all lined up. Some previous studies had methodological fl aws because they did not have separate control groups that took into account differences in age, sex, and education levels that occur between the two types of MS, they pointed out.
STUDY DESIGN
To overcome that shortcoming, the researchers set up a cross-sectional study involving 41 PPMS patients, 60 RRMS patients, and 415 healthy controls. The controls were divided into 20 groups according to age, sex, and education level so there was a good match to each group of MS patients. All participants were at least 18 years old. PPMS patients had symptoms of MS for 14 years or less and the RRMS patients had symptoms less than 10 years. Those with psychiatric illnesses, except for stable depressive symptoms, were excluded from the study.
Nearly 88 percent of both the PPMS patients and the RRMS patients were taking disease-modifying drugs at the time of their examination. The average age was 52 for the PPMS patients and just over 37 for the RRMS, and the PPMS group has a greater proportion of women. Disability, as measured by the Expanded Disability Status Scale -0 to 10, with larger numbers indicating more disability -was 3.5 for the PPMS patients and 1.5 for the RRMS.
All participants underwent a battery of neuropsychological tests that focused on seven cognitive domains: information processing speed, attention, working memory, verbal and visual episodic memory, visuoconstruction, and executive function. Participants were also evaluated for depression, as well as for anxiety and fatigue.
The study authors found that both groups of MS patients fared worse than healthy controls on cognitive testing. PPMS patients performed more poorly overall than the matched healthy controls on 16 out of 23 neuropsychological tests, doing worse in almost all domains except visual episodic memory and visuoconstruction.
"Although cognitive impairment in PPMS has previously been documented, it is noteworthy that the reported rates
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ARTICLE IN BRIEF
Investigators reported that patients with primary progressive multiple sclerosis (PPMS) and relapsing-remitting relapsing MS fared worse than healthy controls on cognitive testing; and PPMS patients performed more poorly overall than the matched healthy controls on 16 out of 23 neuropsychological tests, doing worse in almost all domains except visual episodic memory, and visuoconstruction.
DR. BRUNO BROCHET:
"Although PPMS is mainly characterized clinically by spinal cord involvement, we observed that cognitive functions are frequently impaired. Cognitive impairment appears to be more frequent and severe and concerns a wider range of cognitive functions than in relapsing-remitting MS." vary widely in previously studies (from 7% to 58%)," the researchers wrote. "In our study, 47.4% of patients with PPMS were impaired in at least two cognitive domains."
RRMS patients had lower scores on fi ve out of 23 tests compared with the healthy controls, lagging behind on tests related to information processing speed, attention, and working memory.
Would greater disability in the PPMS group, as measured by EDSS, explain the differences in cognition? Study authors noted that even after controlling for disability and age, cognitive differences emerged in the PPMS and RRMS patients. The PPMS group did worse than the RRMS group on tests that measure working memory and verbal episodic memory.
The researchers noted that the study had some shortcomings because it did not include MRIs of the participants, an element that would have helped researchers "understand the mechanism underlying the cognitive impairments of patients with these different types of MS." The researchers could have utilized MRIs to determine if cognitive impairment correlated with brain changes seen on imaging.
"We have previously shown that cognitive impairment may be a marker of diffuse brain abnormalities in early RRMS patients," they wrote. "The observed group difference in the present study could refl ect the fact that PPMS patients have more widespread brain damage; specifi cally, pathological studies suggest that PPMS patients have diffuse pathology in normal appearing white matter and gray matter injury (both cortical and deep gray matter damage)." Dr. Brochet said in an e-mail interview that the fi ndings should be useful to clinicians who may be evaluating and counseling MS patients who report cognitive diffi culties with work or other activities.
"These results should encourage neurologists to assess cognitive functions in patients with PPMS as part of the clinical workup," Dr. Brochet said. "Since impairment in processing speed is the most frequent defi cit observed in PPMS, focusing on information processing speed could be a good strategy to detect cognitive impairment in routine clinical evaluation. There are a number of interventions that have been evaluated that suggest that cognitive reserve can be improved through increasing physical activity, social interaction and challenging mental activities."
EXPERTS COMMENT
Lauren Krupp, MD, professor of neurology at Stony Brook University Medical Center in New York, told Neurology Today that the new study was an important addition to the understanding of PPMS, which she said is fortunately getting increasing attention from the scientifi c community. She said that this MS patient population has been diffi cult to characterize, in part because the disease is less common than RRMS, and the onset is more subtle and gradual. Patients with PPMS are at great risk in delays in diagnosis and perhaps misdiagnosis. "It' s harder to make the diagnosis and we don't have treatments to offer," she said of PPMS. Sorting out whether cognitive changes are due to the disease itself or in combination with the added effects of aging can also be tough.
"Primary progressive patients tend to be older and those people then are struggling not only from the effects of the disease, but also with decline that can come with aging," she said.
Dr. Krupp said she was recently awarded a grant from the National MS Society to study whether "cognitive retraining" using computer programs to enhance cognition could be helpful for MS patients, including those with PPMS.
Ralph Benedict, PhD, professor of neurology and psychiatry at University at Buffalo, told Neurology Today that he was somewhat surprised by the fi ndings that patients with PPMS have such a greater extent of cognitive impairment than those with RRMS. "Some studies have reported that, but not to this degree," he said.
Dr. Benedict, who studies MS, said one of his research aims is to understand grey matter atrophy and how brain changes affect clinical outcomes. He is also interested in the development of good psychometric measures that could be universally used to study cognitive function in MS patients. 
